Susan Desmond-Hellmann: Herceptin and Drug Development

Desmond-Hellmann discusses the drug development process and shares her experience with the targeted cancer therapeutic, Herceptin.

Download: This Video Subtitled Videos: English
Resources: Transcript (.txt)(.xls)
Trouble Viewing? Try it on iTunes.Report a problem.

Research Papers Discussed in this Talk

Slamon, D.J. et al. (2001)  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  New England Journal of Medicine 344(11):783-792.

Stern, H.M.  (2012)  Improving treatment of HER2-positive cancers: opportunities and challenges. Science Translational Medicine 4(127):1-10.

Educator Resources (Educators only)

These questions and answers were designed to link the iBiology video to the research paper and for use as a classroom activity.

Prepared by Dr. Kirk Ehmsen.

Questions and answers for this talk and related paper >>

About the Speaker

An oncologist and leader in biotechnology, Susan Desmond-Hellmann is currently Chancellor of the University of California San Francisco. Prior to joining UCSF, Desmond-Hellmann spent 14 years at Genentech where she served as President, Product Development from 2004-2009. Under her direction, Genentech became the nation's No. 1 producer of anti-cancer drug treatments.

Related Talks


Speak Your Mind